Monoclonal antibodies and arthritis - PubMed (original) (raw)

. 1990 Jan;29(1-2):77-87.

doi: 10.1007/BF01964727.

Affiliations

• PMID: 2327319
• DOI: 10.1007/BF01964727

Monoclonal antibodies and arthritis

M E Billingham et al. Agents Actions. 1990 Jan.

Abstract

Monoclonal antibodies to certain cell surface constituents on lymphocytes, monocytes and macrophages have been administered to Lewis rats with developing, established or adoptively transferred arthritis, to determine any immunomodulatory properties. Anti-CD4 antibodies against helper T-lymphocytes produced a dose related inhibition of developing arthritis; high dose levels completely suppressed all symptoms of arthritis and these rats were resistant to further attempts to induce arthritis. Anti-Ia (MHCII) antibodies also inhibited arthritis in a dose related manner; anti-pan T antibodies delayed the onset of arthritis, but antibodies against CD8 and IL-2 receptor positive cells were without effect. Development of type II collagen-induced arthritis was also inhibited by anti-CD4 treatment. Established arthritis could be temporarily inhibited by anti-CD4 antibodies, but rebound of arthritis invariably occurred after stopping treatment, as is the case with cyclosporin A. Similar results with anti-CD4 antibodies were obtained during treatment of arthritis adoptively transferred by arthritogenic T-lymphocytes. From these experiments it is clear that CD4 positive T-lymphocytes have a major role in the induction of adjuvant arthritis and that interaction between CD4 and Ia bearing cells is important. The rebound of arthritis that occurred after withdrawal of anti-CD4 treatment during established disease infers that cells in addition to helper T-lymphocytes are involved in the chronicity of arthritis, but these remain to be elucidated. These findings are discussed in relation to results with monoclonal antibodies in other models of arthritis and human rheumatoid arthritis; the prospects for human therapy are also discussed.

PubMed Disclaimer

Similar articles

• Treatment with an anti-CD4 monoclonal antibody strongly ameliorates established rat adjuvant arthritis.
  Pelegrí C, Morante MP, Castellote C, Franch A, Castell M. Pelegrí C, et al. Clin Exp Immunol. 1996 Feb;103(2):273-8. doi: 10.1046/j.1365-2249.1996.d01-624.x. Clin Exp Immunol. 1996. PMID: 8565311 Free PMC article.
• In vivo modulation of murine collagen induced arthritis.
  Ranges GE, Fortin S, Barger MT, Sriram S, Cooper SM. Ranges GE, et al. Int Rev Immunol. 1988 Sep;4(1):83-90. doi: 10.3109/08830188809044772. Int Rev Immunol. 1988. PMID: 3149663 Review.
• Anti-CD2 (OX34) MoAb treatment of adjuvant arthritic rats: attenuation of established arthritis, selective depletion of CD4+ T cells, and CD2 down-modulation.
  Hoffmann JC, Herklotz C, Zeidler H, Bayer B, Westermann J. Hoffmann JC, et al. Clin Exp Immunol. 1997 Oct;110(1):63-71. doi: 10.1046/j.1365-2249.1997.4881385.x. Clin Exp Immunol. 1997. PMID: 9353150 Free PMC article.
• Polyclonal Th1 cells transfer oil-induced arthritis.
  Svelander L, Müssener A, Erlandsson-Harris H, Kleinau S. Svelander L, et al. Immunology. 1997 Jun;91(2):260-5. doi: 10.1046/j.1365-2567.1997.00251.x. Immunology. 1997. PMID: 9227326 Free PMC article.
• Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha.
  Williams RO. Williams RO. Methods Mol Biol. 2007;361:265-84. doi: 10.1385/1-59745-208-4:265. Methods Mol Biol. 2007. PMID: 17172717 Review.

Cited by

• Mechanism of action of Nrf2 and its related natural regulators in rheumatoid arthritis.
  Ma K, Miao L, Li B, Yu W, Liu F, Liu K, Li Y, Huang C, Yang Z. Ma K, et al. J Orthop Surg Res. 2024 Nov 14;19(1):759. doi: 10.1186/s13018-024-05221-w. J Orthop Surg Res. 2024. PMID: 39543632 Free PMC article. Review.
• Anti-rheumatoid arthritis potential of Halodule pinifolia: development, characterization and in vivo evaluation of H. pinifolia-based oral suspension and lipid nano-emulsion.
  Nessa S, Lavanya S, Routray RK, Chaurasiya A, Kulkarni OP, Begum AS. Nessa S, et al. Inflammopharmacology. 2024 Apr;32(2):1203-1223. doi: 10.1007/s10787-024-01431-0. Epub 2024 Mar 7. Inflammopharmacology. 2024. PMID: 38451395
• Expression of cytokine mRNA and protein in joints and lymphoid organs during the course of rat antigen-induced arthritis.
  Pohlers D, Siegling A, Buchner E, Schmidt-Weber CB, Palombo-Kinne E, Emmrich F, Bräuer R, Kinne RW. Pohlers D, et al. Arthritis Res Ther. 2005;7(3):R445-57. doi: 10.1186/ar1689. Epub 2005 Feb 17. Arthritis Res Ther. 2005. PMID: 15899031 Free PMC article.
• Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen-induced arthritis: influence on T helper cell activation.
  Pohlers D, Nissler K, Frey O, Simon J, Petrow PK, Kinne RW, Bräuer R. Pohlers D, et al. Clin Exp Immunol. 2004 Mar;135(3):409-15. doi: 10.1111/j.1365-2249.2003.02381.x. Clin Exp Immunol. 2004. PMID: 15008972 Free PMC article.
• New rat model of Pneumocystis pneumonia induced by anti-CD4(+) T-lymphocyte antibodies.
  Thullen TD, Ashbaugh AD, Daly KR, Linke MJ, Steele PE, Walzer PD. Thullen TD, et al. Infect Immun. 2003 Nov;71(11):6292-7. doi: 10.1128/IAI.71.11.6292-6297.2003. Infect Immun. 2003. PMID: 14573648 Free PMC article.

References

1. 1. Ann Rheum Dis. 1986 Apr;45(4):339-44 - PubMed
2. 1. Nature. 1986 Apr 3-9;320(6061):449-51 - PubMed
3. 1. Eur J Immunol. 1988 Jul;18(7):1079-88 - PubMed
4. 1. Agents Actions. 1986 Dec;19(5-6):295-305 - PubMed
5. 1. Cell Immunol. 1983 Aug;80(1):198-204 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program